Gisela Schwab Exelixis, Inc. (EXEL) insider trading activity

Gisela Schwab is Pres, Prod Dev & Med Aff & CMO of EXELIXIS, INC.. Currently has a direct ownership of 689,078 shares of EXEL, which is worth approximately $23.6 Million. The most recent transaction as insider was on Jul 26, 2021, when has been sold 40,000 shares (Common Stock) at a price of $4.2 per share, resulting in proceeds of $168,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 689K

0% 3M change

0% 12M change

Total Value Held $23.6 Million

Gisela Schwab Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 26 2021	BUY Exercise of conversion of derivative security	$168,000 $4.2 p/Share	40,000 Added 5.49%	689,078 Common Stock
Jul 21 2021	BUY Exercise of conversion of derivative security	$147,000 $4.2 p/Share	35,000 Added 5.12%	649,078 Common Stock
May 13 2021	SELL Open market or private sale	$2,538,000 $25.38 p/Share	100,000 Reduced 14.0%	614,078 Common Stock
May 13 2021	BUY Exercise of conversion of derivative security	$190,000 $1.9 p/Share	100,000 Added 12.28%	714,078 Common Stock
Apr 26 2021	SELL Open market or private sale	$1,250,000 $25.0 p/Share	50,000 Reduced 7.54%	613,482 Common Stock
Apr 26 2021	BUY Exercise of conversion of derivative security	$85,000 $1.7 p/Share	50,000 Added 7.01%	663,482 Common Stock
Apr 01 2021	SELL Open market or private sale	$1,150,000 $23.0 p/Share	50,000 Reduced 7.54%	613,482 Common Stock
Apr 01 2021	BUY Exercise of conversion of derivative security	$85,000 $1.7 p/Share	50,000 Added 7.01%	663,482 Common Stock
Mar 04 2021	BUY Grant, award, or other acquisition	-	72,885 Added 10.62%	613,482 Common Stock
Feb 18 2021	SELL Open market or private sale	$1,117,500 $22.35 p/Share	50,000 Reduced 8.47%	540,597 Common Stock
Feb 18 2021	BUY Exercise of conversion of derivative security	$85,000 $1.7 p/Share	50,000 Added 7.81%	590,597 Common Stock
Feb 17 2021	SELL Open market or private sale	$1,125,000 $22.5 p/Share	50,000 Reduced 8.47%	540,597 Common Stock
Feb 17 2021	BUY Exercise of conversion of derivative security	$85,000 $1.7 p/Share	50,000 Added 7.81%	590,597 Common Stock
Feb 15 2021	SELL Payment of exercise price or tax liability	$62,619 $21.91 p/Share	2,858 Reduced 0.53%	540,597 Common Stock
Feb 03 2021	SELL Payment of exercise price or tax liability	$337,994 $22.56 p/Share	14,982 Reduced 2.68%	543,455 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	81,038 Added 12.67%	558,437 Common Stock
Nov 15 2020	SELL Payment of exercise price or tax liability	$301,452 $20.16 p/Share	14,953 Reduced 3.04%	477,399 Common Stock
Oct 22 2020	SELL Payment of exercise price or tax liability	$1,203,571 $21.79 p/Share	55,235 Reduced 10.1%	491,835 Common Stock
Oct 22 2020	BUY Grant, award, or other acquisition	-	213,879 Added 28.11%	547,070 Common Stock

Also insider at

GNCA

GENOCEA BIOSCIENCES, INC. Healthcare

Director

Gisela Schwab

Pres, Prod Dev & Med Aff & CMO

Alameda, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EXEL shares.

Notify only if

Value

Insider Trading

Get notified when an Exelixis, Inc. insider buys or sells EXEL shares.

Notify only if

Operation

Value

Type

News

Receive news related to EXELIXIS, INC.

Track Activities on EXEL

Account